Deciphering the Fitness Determinants of Clonal Mosaicism

2022 Emerging Leader Award

Dan Landau, MD, PhD, Weill Medical College of Cornell University

Dan Landau, MD, PhD

Cancer mutations drive the outgrowth of small populations of cells in seemingly normal tissue, years before any clinical diagnosis of cancer. However, how such mutations change cellular behavior to provide them with a competitive growth advantage over adjacent normal cells remains poorly understood. To address this gap in knowledge, Dr. Landau is developing and applying novel single-cell sequencing technologies to study the mechanisms underlying the growth advantage in cancer, providing a critical window into the earliest stages of cancer formation.

Dr. Landau is an Associate Professor of Medicine at Weill Cornell Medicine and a Core Member of the New York Genome Center. He received his MD from the Sackler School of Medicine at Tel Aviv University, and his PhD in Cancer Biology from Paris Diderot University. He completed his residency in Internal Medicine and a fellowship in Hematology and Medical Oncology at Yale University, and was a postdoctoral fellow in Cancer Genomics at the Dana-Farber Cancer Institute and the Broad Institute. He is an oncologist whose long-term goal is to develop novel technologies to address cancer evolution as a central obstacle to cure.


Nam AS, Dusaj N, Izzo F, Murali R, Myers RM, Mouhieddine TH, Sotelo J, Benbarche S, Waarts M, Gaiti F, Tahri S, Levine R, Abdel-Wahab O, Godley LA, Chaligne R, Ghobrial I, Landau DA. Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. Nat Genet. 2022.

Ben-Chetrit N, Niu X, Swett AD, Sotelo J, Jiao MS, Stewart CM, Potenski C, Mielinis P, Roelli P, Stoeckius M, Landau DA. Integration of whole transcriptome spatial profiling with protein markers. Nat Biotechnol. 2023.